



GNV31AUSA/UPN-K1774

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1635
James M. Wilson)
) Examiner: Brian A. Whiteman
)
Appln. No. 09/807,802) Confirmation No. 5849
)
Filed: November 29, 2001)
)
For: ADENO-ASSOCIATED VIRUS)
SEROTYPE I NUCLEIC ACID)
SEQUENCES, VECTORS AND HOST)
CELLS CONTAINING SAME) December 23, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and a copy of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and after the receipt of a first Office Action on the merits. Therefore, a fee of \$180.00 is due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

EXPRESS MAIL NO. EU531571956US

CUSTOMER NO. 00270

01/05/2004 SSESHE1 00000079 09807802


01 FC:1806

180.00 DP

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By 
Cathy A. Kedroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Phone: (215) 540-9200
Fax: (215) 540-5818



PTO/SB/08B (04-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/807,802
				Filing Date	April 17, 2001
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	1	of	2	Attorney Docket Number	GNV31AUSA/UPN-K1774

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	CA	US-6,387,368 B1	05-14-2002	Wilson et al	
	CB	US-6,274,354 B1	08-14-2001	Wilson et al	
	CC	US-6,482,634 B1	11-19-2002	Wilson et al	
	CD	US-6,475,769 B1	11-05-2002	Wilson et al	
	CE	US-6,365,394 B1	04-02-2002	Gao et al	
	CF	US-6,399,385 B1	06-04-2002	Croyle et al	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (If known)					
	CG	PCT WO03/093440	A2	11-13-2003	University of Florida		
	CH	PCT WO03/092598	A2	11-13-2003	University of Florida		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-00)



Approved for use
through 4/30/2003.
OMB 0651-0031
U.S. Patent and Trademark Office;
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/807,802
				Filing Date	April 17, 2001
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	2	of	2	Attorney Docket Number	GNV31AUSA/UPN-K1774

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column(s), publisher, city and/or country where published	T ²
	CI	HAUCK ET AL, Generation and Characterization of Chimeric Recombinant AAV Vectors, Molecular Therapy, Vol. 7, No. 3, pp. 419-425, (March 2003)	
	CJ	RABINOWITZ ET AL, Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2002)	
	CK	HAUCK ET AL, Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 77, No. 4, pp. 2768-2774, (February 2003)	
	CL	ARRUDA ET AL, Safety and Efficacy of Factor IX Gene Transfer to Skeletal Muscle in Murine and Canine Hemophilia B Models by Adeno-Associated Viral Vector Serotype 1, Blood First Edition Paper, (September 11, 2003)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.